Department of Neurosurgery, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Neurosurg Rev. 2010 Apr;33(2):175-83; discussion 183-4. doi: 10.1007/s10143-010-0239-8. Epub 2010 Feb 5.
Dissemination of glioblastoma was once considered rare but is now increasingly encountered with longer survival of glioblastoma patients. Despite the potential negative impact of dissemination on clinical outcome, however, molecular markers useful for prediction of dissemination risk still remains ill defined. We tested in this study for an association between the expression of stem cell marker CD133 and the risk of dissemination in 26 cases of glioblastoma (16 with dissemination and 10 without dissemination). The protein expression of CD133 was examined by western blot analysis of tumor specimens, and the CD133 expression levels were quantified by densitometry and normalized to beta-actin. The results indicated that CD133 expression levels are significantly higher in glioblastomas with dissemination (mean 10.3, range 0.20-27.8) than in those without (mean 1.18, range 0.07-3.58). The results suggest that CD133 could be a molecular predictor of glioblastoma dissemination, and also give rise to an intriguing idea that CD133-positive cancer stem cells may be implicated in the initiation of disseminated lesions.
胶质母细胞瘤的播散曾经被认为很少见，但随着胶质母细胞瘤患者的生存时间延长，这种情况越来越常见。然而，尽管播散对临床结果可能有负面影响，但仍然缺乏有用的分子标志物来预测播散风险。在这项研究中，我们检测了 26 例胶质母细胞瘤（16 例有播散，10 例无播散）中干细胞标志物 CD133 的表达与播散风险之间的关系。通过肿瘤标本的 Western blot 分析检测 CD133 的蛋白表达，并通过密度测定法对 CD133 表达水平进行定量，并用β-肌动蛋白进行标准化。结果表明，有播散的胶质母细胞瘤中 CD133 的表达水平明显高于无播散的胶质母细胞瘤（平均值 10.3，范围 0.20-27.8）。结果提示 CD133 可能是胶质母细胞瘤播散的分子预测因子，也引出了一个有趣的想法，即 CD133 阳性的癌症干细胞可能参与了播散病变的发生。
